A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

Altoona Center For Clinical Research, Duncansville

Lehigh Valley Hospital; Dept of Medicine, Allentown

Clinical Research Center of Reading, Wyomissing

Johns Hopkins Uni, Baltimore

Asheville Arthritis & Osteoporosis Center, PA, Asheville

Arthritis & Rheumatology of Georgia, Atlanta

Arthritis & Rheumatism; Disease Specialities, Aventura

Science and Research Institute, Inc., Jupiter

Burnette & Silverfield, MDS, Tampa

Sarasota Arthritis Center; Research Dept, Sarasota

Arthritis Center Palm Harbor, Palm Harbor

Arthritis Rsrch of Florida, Inc., Palm Harbor

Rheumatology Associates of North Alabama, Huntsville

Pinnacle Research Group; Llc, Central, Anniston

Jackson Arthritis Clinic, Flowood

Borgess Research Institute, Kalamazoo

Deerbrook Medical Associates, Vernon Hills

Physicians Group, LC DBA Rheumatology & Internal Medicine Associates, St Louis

Health Research of Oklahoma, Llc, Oklahoma City

Houston Inst. For Clinical Research, Houston

Texas Research Center, Sugar Land

Advanced Arthritis Care & Research, Scottsdale

Catalina Pointe Clinical Research, Inc., Tucson

Pacific Arthritis Care Center, Los Angeles

South Puget Sound Clinical Research, Olympia

NJP Clinical Research, Clifton

The Governors of the Uni of Alberta; Heritage Medical Research Centre, Edmonton

Laurel Medical Clinic, Vancouver

Manitoba Clinic, Winnipeg

Nexus Clinical Research Centre, St. John's

Dr. William G. Bensen Medicine Professional Corporation, Hamilton

Credit Valley, Rheumatology, Mississauga

Rheumatology Research Associates, Ottawa

Private Practice, Toronto

Chus Hopital Fleurimont, Sherbrooke

Centre Re Recherche Saint-Louis, Québec

Ponce School of Medicine; Caimed Center, Ponce

Glasgow Royal Infirmary; Centre For Rheumatic Diseases, Glasgow

Trafford General Hospital; Rheumatology, Manchester

Royal Victoria Infirmary; Clinical Research Facility, Newcastle upon Tyne